Synergy CHC Corp.
Close on Oct 19, 2026
- Market cap
- $90.43K
- P/E (TTM)
- –
- Dividend yield
- –
About Synergy CHC
Medicinal Chemicals & Botanical Products, SIC 2833
Synergy CHC Corp. is a provider of consumer healthcare, beauty, and wellness lifestyle products. The company focuses on the nutraceutical market with two core marquee brands: FOCUSfactor, a clinically tested brain-health supplement formulated to support memory, concentration, and focus, and Flat Tummy, a female-focused lifestyle and wellness line featuring nutritional shakes, teas, lollipops, supplements, and fitness accessories. In addition, FOCUSfactor has expanded into ready-to-drink energy beverages and liquid shots. Synergy sells products to consumers through leading club, mass, and drug retail partners—including Costco, Amazon.com, Walmart, Walgreens, BJ’s, and The Vitamin Shoppe—as well as direct to consumers through its brand websites and mobile applications.
The company operates an asset-light model utilizing third-party contract manufacturing partners. Primarily serving North American customers, Synergy operates in the United States and has expanded distribution into Canada and Mexico. Synergy CHC Corp. is headquartered in North Windham, Maine.
Summary of the business section of Synergy CHC's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Synergy CHC Corp.
- Founded
- 2010
- Headquarters
- Westbrook, ME
- Address
- 865 Spring Street 04092
- Phone
- (615) 939-9004
- Employees
- 28, Dec 31, 2025
- Industry
- Medicinal Chemicals & Botanical Products
- Incorporated in
- Nevada
- Fiscal year ends
- December 31
- Auditor
- RBSM LLP, Houston, Texas
Stock & identifiers
- Ticker
- SNYRQ
- Exchange
- OTC
- IPO date
- Oct 23, 2024
- Shares outstanding
- 15M, May 11, 2026
- Public float
- $13.01M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1562733
- CUSIP
- 87165D208
- ISIN
- US87165D2080
- EIN
- 99-0379440
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jack Ross | CEO and Chairman, Director | 4,795,757 |
| Alfred Baumeler | President, Director | – |
| Jaime Fickett | Chief Financial Officer | – |
| Nitin Kaushal | Director | 306,433 |
| Teresa Brigid Thompson | Director | 25,824 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Jack Ross | $1.14M | $1.14M | $394.61K | $0 | – |
| FY2024 Jack Ross | $1.32K | $1.32K | $328.29K | $0 | – |
| FY2023 Jack Ross | $520.00K | $520.00K | $396.09K | $0 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“we had 28 full-time employees.”
Corporate history
Events identified from SEC filings